Inventor
YUGUANG WANG
Inventor
CN
Overview
Patents· 8 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes23%
C07CAcyclic or carbocyclic compounds23%
C07DHeterocyclic compounds23%
C07BGeneral methods of organic chemistry19%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations10%
B01JChemical or physical processes, e.g. catalysis or colloid chemistry3%
PatentTitleYear
12,473,300Thienopyrimidine derivative and preparation method therefor202512,428,369Crystal form of aromatic vinyl derivatives, and preparation method therefor and use thereof202512,275,724Processes and intermediates for the preparation of soluble guanylate cyclase stimulators202512,030,874Processes and intermediates for the preparation of soluble guanylate cyclase stimulators202411,708,361Processes and intermediates for the preparation of soluble guanylate cyclase stimulators202311,384,048Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application202211,352,368Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof202211,274,096Processes and intermediates for the preparation of soluble guanylate cyclase stimulators2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2025Patents assigned to CYCLERION THERAPEUTICS INC (4)· patent assignee history
2022–2025Patents assigned to GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD (4)· patent assignee history
2022–2025Based in CN· patent location history
2022–2025Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| CYCLERION THERAPEUTICS INC | 4 | 2022–2025 |
| GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD | 4 | 2022–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| CN | 4 | 2022–2025 |
| US | 4 | 2022–2025 |